Paragon Advisors LLC Acquires 935 Shares of RxSight, Inc. (NASDAQ:RXST)

Paragon Advisors LLC boosted its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 3.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,399 shares of the company’s stock after buying an additional 935 shares during the quarter. Paragon Advisors LLC’s holdings in RxSight were worth $1,552,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. CWM LLC raised its stake in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company’s stock valued at $29,000 after buying an additional 521 shares in the last quarter. Quest Partners LLC purchased a new position in shares of RxSight during the second quarter worth about $41,000. Amalgamated Bank increased its holdings in shares of RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after purchasing an additional 207 shares in the last quarter. Finally, KBC Group NV grew its holdings in RxSight by 63.6% during the 3rd quarter. KBC Group NV now owns 1,232 shares of the company’s stock valued at $61,000 after buying an additional 479 shares during the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other RxSight news, Director Jesse Anderson Corley bought 11,111 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were bought at an average price of $45.37 per share, for a total transaction of $504,106.07. Following the transaction, the director now directly owns 468,571 shares in the company, valued at $21,259,066.27. This trade represents a 2.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ilya Goldshleger sold 1,330 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $46.13, for a total value of $61,352.90. Following the transaction, the insider now owns 42,246 shares in the company, valued at $1,948,807.98. This trade represents a 3.05 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,745 shares of company stock worth $2,240,200. Company insiders own 9.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Stifel Nicolaus reduced their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Jefferies Financial Group assumed coverage on RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target for the company. Oppenheimer cut their price objective on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Finally, Wells Fargo & Company decreased their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $61.63.

RxSight Stock Up 2.0 %

Shares of RXST stock opened at $45.05 on Friday. The stock’s fifty day simple moving average is $50.32 and its 200 day simple moving average is $53.27. RxSight, Inc. has a twelve month low of $27.07 and a twelve month high of $66.54. The firm has a market capitalization of $1.82 billion, a P/E ratio of -54.28 and a beta of 1.19.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.